Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc., a biopharmaceutical company, engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing two antagonist PD-1 antibodies, ENUM 388D4 and ENUM 288C4 for use in treating cancer. The company is also developing antibody drug candidates for various immunomodulatory protein targets, including TIM-3, LAG-3, OX40, TIGIT, and VISTA. Enumeral Biomedical Holdings, Inc. has collaboration agreements with Merck Sharp & Dohme Corp.; and The University of Texas MD Anderson Cancer Center, as well as a research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was f...
200 CambridgePark Drive
Cambridge, MA 02140
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc. does not have any Key Executives recorded.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2016
Nov 10 16
Enumeral Biomedical Holdings, Inc. announced unaudited consolidated earnings results for the third quarter ended September 30, 2016. For the quarter, the company reported net loss of $1,260,850 or $0.02 per diluted share compared to net income of $618,284 or $0.01 per diluted share reported in the same period last year. Total revenue was $320,811 against $483,825 reported last year. Loss from operations was $1,518,480 against $2,668,480 reported last year. Net loss before income taxes was $1,260,850 against net income before income taxes of $618,284 reported last year. Net loss for the quarter was primarily due to a decrease of $2,871,515 in the change in the fair value of derivative liabilities and a decrease of $163,014 in revenue, offset by a decrease of $1,313,014 in operating expenses.
Enumeral Biomedical Holdings, Inc. Announces Executive Changes
Sep 22 16
Enumeral Biomedical Holdings, Inc. announced that Wael Fayad has been appointed Chairman, President, and Chief Executive Officer of the Company, effective as of September 21, 2016. Mr. Fayad brings to Enumeral more than two decades of senior executive and business development experience in the life sciences industry. From 2001 to 2014, Mr. Fayad held positions of increasing responsibility at Forest Laboratories, Inc., most recently as Corporate Vice President, Global Business Development. In that role, he was responsible for business development and alliance management, including the identification, assessment and negotiation of multiple business opportunities. Mr. Fayad helped build and manage a broad network of partnerships at Forest, and upon Forest’s acquisition by Actavis, Mr. Fayad also assisted with the integration of the two companies. In connection with Mr. Fayad’s appointment as Chairman, President, and Chief Executive Officer, John J. Rydzewski stepped down as Enumeral’s Executive Chairman and from the Company’s Board of Directors. Arthur H. Tinkelenberg, Ph.D., Enumeral’s former President and Chief Executive Officer, also stepped down from the Company’s Board of Directors.
Enumeral Biomedical Holdings, Inc. Announces the Resignation of Anhco Nguyen, Ph.D. as Vice President of Research and Development
Aug 19 16
On August 17, 2016, Anhco Nguyen, Ph.D. resigned from his position as Vice President of Research and Development for Enumeral Biomedical Holdings, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 29, 2016